Diabetic Retinopathy Market To Reach $13.77 Billion By 2030

Diabetic Retinopathy Market Growth & Trends

The global diabetic retinopathy market is anticipated to reach USD 13.77 billion by 2030 and expand at a CAGR of 6.4% during the forecast period, according to a new report by Grand View Research, Inc. Rising incidence of diabetes in multiple regions and growing awareness regarding the significance of efficient management and effective treatment of Diabetic Retinopathy (DR) are key market drivers. If not treated in time, DR may result in severe vision impairment or even blindness. Improved healthcare infrastructure and increasing accessibility to modern treatments are expected to fuel market growth.

The significant increase in the number of individuals diagnosed with diabetes across multiple regions contributes to growth of this market. Rising awareness regarding the importance of early detection and effective management of blood glucose levels, which reduces the chances of DR, also fuels the market growth. Furthermore, the alarming statistics related to the increasing cases of diabetes-related blindness also increase are expected to support growth of this market.

A report from the American Diabetes Association states that people with diabetes are at risk of developing eye diseases, such as glaucoma, cataracts, and macular edema. DR is considered one of the main reasons for blindness in the U.S. According to the U.S. Centers for Disease Control and Prevention, nearly 38.4 million individuals have diabetes in the U.S.

 Request a free sample copy or view report summary: Diabetic Retinopathy Market Report

Diabetic Retinopathy Market Report Highlights

• Non-proliferative diabetic retinopathy dominated the market with more than 70.0% share in 2024 owing increasing awareness regarding importance of early detection and timely treatment.

• Laser surgery is expected to grow at the fastest CAGR over the forecast period.

• The anti-VEGF management segment held the largest market share of 92.3% in 2024.

• The rise in healthcare investments and advancements in technology contribute to market growth.

• North America dominated the global market owing to increasing awareness, sophisticated healthcare infrastructure, and high market penetration of anti-VEGF drugs.

• In September 2024, India's national regulatory authority approved an ophthalmic AI software, Remidio Medios DR AI, which facilitates the automatic detection of referable DRs.

Diabetic Retinopathy Market Segmentation

Grand View Research has segmented the global diabetic retinopathy market on the basis of type, management, and region:

Diabetic Retinopathy Type Outlook (Revenue, USD Million, 2018 - 2030)

• Proliferative Diabetic Retinopathy

• Non-proliferative Diabetic Retinopathy

Diabetic Retinopathy Management Outlook (Revenue, USD Million, 2018 - 2030)

• Anti-VEGF

• Intraocular Steroid Injection

• Laser Surgery

• Vitrectomy

Diabetic Retinopathy Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Thailand

  • Australia

• Latin America

  • Brazil

  • Argentina

  • Mexico

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Diabetic Retinopathy Market

• Bayer AG

• AbbVie Inc.

• Novartis AG

• Oxurion NV.

• Sirnaomics, Inc.

• Alimera Sciences

• Ampio Pharmaceuticals Inc.

• BCN Peptides

• Kowa Company, Ltd.

• Genentech, Inc.